Developer docs
API playgroundTry for free, no card

Search company profiles

TidalSense

Full company profile

uuid0000e4m

Namestring
TidalSense
Legal namestring
TidalSense Ltd.
Websiteurl
tidalsense.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

TidalSense Ltd. is a Cambridge-based respiratory diagnostics company that has built the N-Tidal platform, comprising the CE-marked Class 2a N-Tidal Diagnose point-of-care COPD diagnostic and the N-Tidal Capture remote patient monitoring solution. The platform combines a patented CO2 breath sensor — developed over more than ten years — with a 4G-connected handheld device that automatically transmits breath data to a cloud backend, where machine learning algorithms trained on over 2.5 million breaths from clinical trials produce diagnostic and longitudinal monitoring outputs. The company targets NHS Integrated Care Boards, respiratory patients, and pharmaceutical companies conducting respiratory clinical trials, with NHS Suffolk and North East Essex ICB disclosed as its first commissioning customer in November 2025.

The business model is a fully managed diagnostic service delivered to NHS ICBs and healthcare providers, in which the device, sensor, connectivity, cloud, and AI analysis are bundled rather than sold as capital equipment. Pricing is negotiated at the ICB level and is not publicly disclosed, and revenue is not yet reported. Marketing reach is concentrated in earned media and LinkedIn-led digital channels, and the company is registered as a private limited company in England and Wales with funding to date from Business Growth Fund, Downing Ventures, Foresight Group, and a series of SBRI Healthcare grants.

Strategically, TidalSense is positioned at the start of its commercial scale-up phase: regulatory clearance under EU MDR has just been obtained, the first NHS commissioning has been announced, and an additional monitoring product (N-Tidal Capture) has been launched to extend the platform into longitudinal care. Competitive positioning rests on the patented sensor, the proprietary breath dataset, regulatory clearance, and a managed-service delivery model intended to reduce operational burden on healthcare providers while creating a recurring revenue stream as more ICBs adopt the diagnostic.

Short descriptiontext

TidalSense is a Cambridge-based medical device company that combines a patented CO2 breath sensor with AI algorithms trained on over 2.5 million breaths to deliver point-of-care COPD diagnosis and remote respiratory monitoring as a managed service to NHS Integrated Care Boards, pharmaceutical trial sponsors, and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory diagnostics platform, COPD diagnostic device, remote respiratory monitoring, AI breath analysis, medical device software
Product category
Respiratory Diagnostics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Managed Diagnostic Services
TypeManaged Services
Description

N-Tidal Diagnose is delivered as a fully managed service to healthcare providers, providing point-of-care COPD diagnostic testing. This model generates recurring revenue through service contracts with NHS ICBs and healthcare systems.

tidalsense.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1N-Tidal®
Description

A powerful platform for diagnosing, monitoring and improving respiratory health through a best in class sensor, an easy-to-use device and regulated, secure, platform driven by exponentially powerful AI

tidalsense.com
+2 more records
Core offering1 text field

TidalSense develops and sells the N-Tidal respiratory intelligence platform, a CE-marked Class 2a medical device that combines a patented CO2 sensor and 4G-connected handheld device with a cloud-based AI platform to diagnose and monitor respiratory conditions. Its core commercial offerings are N-Tidal Diagnose (rapid point-of-care COPD diagnosis) and N-Tidal Capture (remote patient monitoring for longitudinal respiratory assessment), delivered as fully managed services to NHS Integrated Care Boards, healthcare providers, and pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces COPD diagnosis waiting times
+2 more records
Product overview1 text field

TidalSense offers the N-Tidal® platform comprising two core products: N-Tidal® Diagnose (a CE-marked Class 2a medical device for point-of-care COPD diagnosis delivered as a fully managed service) and N-Tidal® Capture (a remote patient monitoring solution for longitudinal respiratory health assessment). Both products share a common patented CO2 sensor technology and connect via 4G to a cloud platform driven by AI algorithms that were trained on over 2.5 million breaths from clinical trials.

Product and service2 records
1N-Tidal® Diagnose
CategoryRespiratory Diagnostics
Description

CE-marked Class 2a medical device under EU MDR providing rapid, accurate, point-of-care COPD diagnostic testing delivered as a fully managed service to NHS Integrated Care Boards and healthcare providers.

2N-Tidal® Capture
CategoryRemote Patient Monitoring
Description

Remote patient monitoring solution powered by N-Tidal digital biomarkers, enabling longitudinal assessment of respiratory health for patients with COPD, asthma, and other respiratory conditions.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Digital respiratory health company offering remote spirometry and care management for COPD and asthma patients — directly overlapping with TidalSense's N-Tidal Diagnose and Capture products and target customer base (healthcare providers and payers).

TypeDirect peer
Description

Digital respiratory health platform (now part of ResMed) using sensors and software to monitor inhaler use in COPD/asthma — comparable in respiratory digital diagnostics, chronic disease management focus, and pharma-partnered business model.

TypeDirect peer
Description

UK-based manufacturer of spirometry and respiratory diagnostic devices used in clinical trials and primary care — directly competes with TidalSense on respiratory measurement hardware and on the clinical workflow for COPD diagnosis.

TypeDirect peer
Description

Global spirometry device manufacturer with connected/smart spirometers for primary care, occupational health, and clinical research — competes with N-Tidal on the underlying respiratory diagnostic device category.

TypeDirect peer
Description

Digital respiratory health company with connected inhaler sensors and spirometry — overlapping with TidalSense on COPD/asthma digital diagnostics and remote monitoring, serving similar healthcare-provider and pharma customers.

6HGE Health
TypeDirect peer
Description

COPD-focused digital health platform offering remote symptom monitoring and care coordination — a direct peer in COPD-specific respiratory digital care pathways and provider-facing solutions.

7Respiri
TypeDirect peer
Description

Respiratory health technology company developing wheeze detection and remote monitoring for asthma and COPD — closely comparable in remote respiratory diagnostics and consumer/provider facing hardware-plus-AI model.

TypeBroad incumbent
Description

Large clinical trial technology services provider offering respiratory endpoints and eCOA across Phase II/III trials — directly relevant to TidalSense's pharma clinical-trial use case, though operating as a broad incumbent across many therapeutic areas.

TypeBroad incumbent
Description

Global respiratory pharma with major COPD/asthma franchises (Symbicort, Breztri, Trixeo) and active digital respiratory initiatives — a relevant pharma customer/partner and a major force shaping COPD care pathways that TidalSense targets.

10Spire Health
TypeEmerging player
Description

Wearable respiratory monitoring company focused on continuous tracking of lung function and respiratory patterns — emerging overlap with TidalSense's remote patient monitoring roadmap and respiratory biomarker development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TidalSense

Respiratory Diagnosticstidalsense.com

TidalSense is a Cambridge-based medical device company that combines a patented CO2 breath sensor with AI algorithms trained on over 2.5 million breaths to deliver point-of-care COPD diagnosis and remote respiratory monitoring as a managed service to NHS Integrated Care Boards, pharmaceutical trial sponsors, and patients.

What TidalSense does

TidalSense Ltd. is a Cambridge-based respiratory diagnostics company that has built the N-Tidal platform, comprising the CE-marked Class 2a N-Tidal Diagnose point-of-care COPD diagnostic and the N-Tidal Capture remote patient monitoring solution. The platform combines a patented CO2 breath sensor — developed over more than ten years — with a 4G-connected handheld device that automatically transmits breath data to a cloud backend, where machine learning algorithms trained on over 2.5 million breaths from clinical trials produce diagnostic and longitudinal monitoring outputs. The company targets NHS Integrated Care Boards, respiratory patients, and pharmaceutical companies conducting respiratory clinical trials, with NHS Suffolk and North East Essex ICB disclosed as its first commissioning customer in November 2025.

The business model is a fully managed diagnostic service delivered to NHS ICBs and healthcare providers, in which the device, sensor, connectivity, cloud, and AI analysis are bundled rather than sold as capital equipment. Pricing is negotiated at the ICB level and is not publicly disclosed, and revenue is not yet reported. Marketing reach is concentrated in earned media and LinkedIn-led digital channels, and the company is registered as a private limited company in England and Wales with funding to date from Business Growth Fund, Downing Ventures, Foresight Group, and a series of SBRI Healthcare grants.

Strategically, TidalSense is positioned at the start of its commercial scale-up phase: regulatory clearance under EU MDR has just been obtained, the first NHS commissioning has been announced, and an additional monitoring product (N-Tidal Capture) has been launched to extend the platform into longitudinal care. Competitive positioning rests on the patented sensor, the proprietary breath dataset, regulatory clearance, and a managed-service delivery model intended to reduce operational burden on healthcare providers while creating a recurring revenue stream as more ICBs adopt the diagnostic.

TidalSense firmographics

Firmographics
Name
TidalSense
Legal name
TidalSense Ltd.
Website
https://tidalsense.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
TidalSense is a Cambridge-based medical device company that combines a patented CO2 breath sensor with AI algorithms trained on over 2.5 million breaths to deliver point-of-care COPD diagnosis and remote respiratory monitoring as a managed service to NHS Integrated Care Boards, pharmaceutical trial sponsors, and patients.
Ownership category
akta.pro rank

Where TidalSense is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

TidalSense business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Managed Diagnostic Services: N-Tidal Diagnose is delivered as a fully managed service to healthcare providers, providing point-of-care COPD diagnostic testing. This model generates recurring revenue through service contracts with NHS ICBs and healthcare systems.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

TidalSense product offering

Product offering

Core offering

TidalSense develops and sells the N-Tidal respiratory intelligence platform, a CE-marked Class 2a medical device that combines a patented CO2 sensor and 4G-connected handheld device with a cloud-based AI platform to diagnose and monitor respiratory conditions. Its core commercial offerings are N-Tidal Diagnose (rapid point-of-care COPD diagnosis) and N-Tidal Capture (remote patient monitoring for longitudinal respiratory assessment), delivered as fully managed services to NHS Integrated Care Boards, healthcare providers, and pharmaceutical companies.

Product overview

TidalSense offers the N-Tidal® platform comprising two core products: N-Tidal® Diagnose (a CE-marked Class 2a medical device for point-of-care COPD diagnosis delivered as a fully managed service) and N-Tidal® Capture (a remote patient monitoring solution for longitudinal respiratory health assessment). Both products share a common patented CO2 sensor technology and connect via 4G to a cloud platform driven by AI algorithms that were trained on over 2.5 million breaths from clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • N-Tidal®: A powerful platform for diagnosing, monitoring and improving respiratory health through a best in class sensor, an easy-to-use device and regulated, secure, platform driven by exponentially powerful AI
  • N-Tidal® Diagnose
  • N-Tidal® Capture

Products and services

  • N-Tidal® Diagnose CE-marked Class 2a medical device under EU MDR providing rapid, accurate, point-of-care COPD diagnostic testing delivered as a fully managed service to NHS Integrated Care Boards and healthcare providers.
  • N-Tidal® Capture Remote patient monitoring solution powered by N-Tidal digital biomarkers, enabling longitudinal assessment of respiratory health for patients with COPD, asthma, and other respiratory conditions.

Quantifiable outcome

  • Reduces COPD diagnosis waiting times
  • +2 more outcomes

Companies that use TidalSense

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

TidalSense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

TidalSense partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

TidalSense competitors and assessment

Company assessment

Direct peers

  • NuvoAir: Digital respiratory health company offering remote spirometry and care management for COPD and asthma patients — directly overlapping with TidalSense's N-Tidal Diagnose and Capture products and target customer base (healthcare providers and payers).
  • Propeller Health: Digital respiratory health platform (now part of ResMed) using sensors and software to monitor inhaler use in COPD/asthma — comparable in respiratory digital diagnostics, chronic disease management focus, and pharma-partnered business model.
  • Vitalograph: UK-based manufacturer of spirometry and respiratory diagnostic devices used in clinical trials and primary care — directly competes with TidalSense on respiratory measurement hardware and on the clinical workflow for COPD diagnosis.
  • MIR (Medical International Research): Global spirometry device manufacturer with connected/smart spirometers for primary care, occupational health, and clinical research — competes with N-Tidal on the underlying respiratory diagnostic device category.
  • Cohero Health: Digital respiratory health company with connected inhaler sensors and spirometry — overlapping with TidalSense on COPD/asthma digital diagnostics and remote monitoring, serving similar healthcare-provider and pharma customers.
  • HGE Health: COPD-focused digital health platform offering remote symptom monitoring and care coordination — a direct peer in COPD-specific respiratory digital care pathways and provider-facing solutions.
  • Respiri: Respiratory health technology company developing wheeze detection and remote monitoring for asthma and COPD — closely comparable in remote respiratory diagnostics and consumer/provider facing hardware-plus-AI model.

Broad incumbents

  • Clario: Large clinical trial technology services provider offering respiratory endpoints and eCOA across Phase II/III trials — directly relevant to TidalSense's pharma clinical-trial use case, though operating as a broad incumbent across many therapeutic areas.
  • AstraZeneca: Global respiratory pharma with major COPD/asthma franchises (Symbicort, Breztri, Trixeo) and active digital respiratory initiatives — a relevant pharma customer/partner and a major force shaping COPD care pathways that TidalSense targets.

Emerging players

  • Spire Health: Wearable respiratory monitoring company focused on continuous tracking of lung function and respiratory patterns — emerging overlap with TidalSense's remote patient monitoring roadmap and respiratory biomarker development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

TidalSense social profiles

Digital presence

TidalSense compliance and trust

Trust signal

Compliance1 record

TidalSense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TidalSense leadership team

Management profile

Number of profiles

Profiles1 record

TidalSense funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TidalSense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TidalSense

What does TidalSense do?

TidalSense develops and sells the N-Tidal respiratory intelligence platform, a CE-marked Class 2a medical device that combines a patented CO2 sensor and 4G-connected handheld device with a cloud-based AI platform to diagnose and monitor respiratory conditions. Its core commercial offerings are N-Tidal Diagnose (rapid point-of-care COPD diagnosis) and N-Tidal Capture (remote patient monitoring for longitudinal respiratory assessment), delivered as fully managed services to NHS Integrated Care Boards, healthcare providers, and pharmaceutical companies.

Is TidalSense a public or private company?

TidalSense is a private company. It is classified as venture growth investor backed and is currently operating.

When was TidalSense founded?

TidalSense was founded in 2013. It employs 11 to 50 people.

Where is TidalSense based?

TidalSense is headquartered in Cambridge, United Kingdom, in the Europe region.

How does TidalSense make money?

One revenue line is on record: managed Diagnostic Services.

Who are TidalSense's main competitors?

Direct peers on record are NuvoAir, Propeller Health, Vitalograph, MIR (Medical International Research), Cohero Health, HGE Health and Respiri. Broad incumbents are Clario and AstraZeneca. Spire Health is listed as an emerging player.

Does TidalSense have an API?

No public API is recorded for TidalSense.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech.euCOPD diagnosis is broken. TidalSense wants to fix it with 75 seconds of breathingTidalSense, a UK medtech company, developed a diagnostic platform for COPD using a 75-second breathing test that captures a CO₂ waveform. The test is faster than spirometry, requires no forced maneuvers, and is being piloted in the UK. The company also aims to expand into asthma diagnosis, particularly in children.TrendHunter.comRespiratory Monitoring DevicesTidalSense, a Cambridge-based company, has raised $19 million to expand its AI-powered respiratory diagnostic platform across Europe and enter the U.S. market. The funding will support the commercialization of its N-Tidal Diagnose system, which uses AI to identify chronic obstructive pulmonary disease (COPD) from breath waveforms, and extend the technology to other conditions like asthma.BioWorldTidalsense raises $19M for AI-powered COPD diagnostic platformTidalsense raised $19 million for its AI-powered N-Tidal Diagnose platform, which detects COPD in five minutes via a 75-second breath test. The funds will support commercialization in the U.K., Ireland, and Europe, prepare for U.S. entry, and expand into asthma.MenlotimesTidalSense Secures $19M to Transform Respiratory Diagnostics Starting with a COPD Breath Test to Cut Patient Wait TimesTidalSense raised $19M to accelerate COPD diagnosis via its N-Tidal Diagnose handheld device, which uses AI to analyze breath CO₂ waveforms. The device, trained on 2.5M breaths, achieved over 90% diagnostic performance and received CE marking in 2025. Funding will support UK, EU, and US expansion and deployment into asthma.BusinessCloudTidalSense raises £14m to take on UK’s third-biggest killerTidalSense raised £14m to commercialize its N-Tidal Diagnose breath test for COPD, which uses AI to analyze CO₂ waveforms. The device, CE-marked in March 2025, was launched in the NHS in September 2025 and is being expanded globally, including to the USA.Pulse 2.0TidalSense Raises £19 Million To Accelerate COPD Diagnostic TechnologyTidalSense raised £19 million in a funding round backed by Cross-Border Impact Ventures, BGF, Airstream Capital, and Foresight Group to accelerate its N-Tidal Diagnose COPD diagnostic test. The test diagnoses COPD in five minutes using normal breathing, unlike the 180-year-old spirometry standard that requires forced exhalation. The funding will support commercialization across the UK, Ireland, and Europe, as well as expansion into the United States.MobiHealthNewsTidalSense raises $19M to improve COPD diagnosticsTidalSense, a Cambridge-based medical device company, raised $19 million in a funding round led by new investor Cross-Border Impact Ventures with participation from BGF, Airstream Capital, and Foresight Group. The financing brings the company's total funding to $40 million and will be used to accelerate commercialization in Europe, enter the U.S. market, and expand its AI-powered COPD diagnostic platform to additional respiratory conditions including asthma. The company's N-Tidal Diagnose device, which received CE mark approval in March 2025, is already in use across NHS settings in the UK.VestbeeTidalSense lands $19M to scale AI-powered COPD breath test globallyCambridge-based healthtech firm TidalSense secured $19 million in funding led by Cross-Border Impact Ventures, with participation from BGF, Airstream Capital, and Foresight Group. The investment will accelerate commercialization of the company's AI-powered respiratory diagnostics platform, support expansion across the UK, Europe, and the US, and fund development of new applications for respiratory conditions beyond COPD. TidalSense's flagship product N-Tidal Diagnose uses a handheld AI device to analyze breathing patterns and carbon dioxide waveforms to detect chronic obstructive pulmonary disease without traditional spirometry testing.The SaaS NewsTidalSense Raises $19M in FundingTidalSense, a Cambridge-based AI-powered respiratory diagnostics company, has secured $19 million in Series funding to accelerate commercialization of its non-invasive COPD testing platform. The round, bringing total funding to $40 million, included investments from Cross-Border Impact Ventures, BGF, AirstStream Capital, and Foresight Group. The capital will support geographic expansion into the UK, Ireland, Europe, and the United States, while also funding development of diagnostics for additional respiratory conditions such as asthma.FinSMEsTidalSense Raises $19M in FundingTidalSense, a Cambridge-based AI-powered respiratory diagnostics company, has raised $19M in financing from Cross-Border Impact Ventures, BGF, Airststream Capital, and Foresight Group, bringing its total funding to $40M. The company plans to accelerate commercialization in the UK, Ireland, and Europe, enter the US market, and expand its diagnostic platform to cover asthma alongside its existing COPD testing solution. TidalSense's N-Tidal Diagnose device is currently deployed across NHS regions in England, Scotland, and Wales.